Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Completed · Phase 3 · NCT03734029
Conditions: Breast Cancer
At a glance
- Research payments reported, 2025
- $141,395
- U.S. investigators named
- 12
- Sites paid
- 10
- Planned or actual enrollment
- 557
About the trial
- Sponsor
- Daiichi Sankyo (with Daiichi Sankyo Co., Ltd., AstraZeneca)
- Tested
- Trastuzumab deruxtecan (DS-8201a) (drug), Capecitabine (drug), Eribulin (drug), Gemcitabine (drug), Paclitaxel (drug), Nab-paclitaxel (drug)
- Dates
- Started 2018-12-27; completion 2026-05-19
- Results posted
- Yes
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: * Cannot be removed by an operation * Has spread to other parts of the body
From ClinicalTrials.gov, last updated 2026-09-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $141,395 in research payments for this study in 2025 (79 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Chan, MD Hematology & Oncology · Torrance, CA
- Fauzia Riaz, MD Medical Oncology · Stanford, CA
- Hope S. Rugo, MD Hematology · San Francisco, CA
- John E. Mcknight, M.D. Hematology & Oncology · Washington, DC
- Adriana M. Milillo Naraine, MD Hematology & Oncology · Pembroke Pines, FL
- Alejandra Perez, MD Hematology & Oncology · Hollywood, FL
- Eugene R. Ahn, M.D. Medical Oncology · Chicago, IL
- Scott A. Sonnier, MD Hematology & Oncology · New Orleans, LA
- Haythem Y. Ali, M.D. Medical Oncology · Detroit, MI
- Vanessa M. Johnson, M.D., M.P.H. Hematology & Oncology · Durham, NC
- Shanu Modi, MD Medical Oncology · New York, NY
- Halle C. Moore, M.D. Hematology & Oncology · Cleveland, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Translational Research in Oncology (trio) $114,625
- University of Miami $18,015
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $3,577
- Ctca Clinical Research Inc. $2,556
- Board of Trustees of the Leland Stanford Junior University $741
- Elligo Health Research $668
- Cleveland Clinic, OH $496
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $326
- Eastern Connecticut Hematology and Oncology Associates $281
- Henry Ford Health Hospital, MI $111
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.